The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...
Researchers have employed Bayesian neural network approaches to evaluate the distributions of independent and cumulative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback